- STAT+: Pharmalittle: We’re reading about FDA views on a Duchenne drug, GSK cost savings, and moreThe FDA said a Capricor stem cell treatment for Duchenne muscular dystrophy did not meet a Phase 3 trial's objectives — contrary to company claims
- STAT+: Three questions with Whoop’s new CMOIn this edition of STAT Health Tech: A chat with Whoop's new chief medical officer, an update on CMS health tech initiative, and more.